Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Receivables - Other: 2015-2025

Historic Receivables - Other for ImmunityBio (IBRX) over the last 10 years, with Sep 2025 value amounting to $1.7 million.

  • ImmunityBio's Receivables - Other rose 130.86% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year increase of 130.86%. This contributed to the annual value of $2.0 million for FY2023, which is 6.83% up from last year.
  • Latest data reveals that ImmunityBio reported Receivables - Other of $1.7 million as of Q3 2025, which was up 725.00% from $204,000 recorded in Q2 2025.
  • In the past 5 years, ImmunityBio's Receivables - Other ranged from a high of $5.0 million in Q2 2022 and a low of $204,000 during Q2 2025.
  • In the last 3 years, ImmunityBio's Receivables - Other had a median value of $1.6 million in 2023 and averaged $1.4 million.
  • As far as peak fluctuations go, ImmunityBio's Receivables - Other surged by 1,711.50% in 2021, and later slumped by 80.16% in 2025.
  • Over the past 5 years, ImmunityBio's Receivables - Other (Quarterly) stood at $1.3 million in 2021, then soared by 41.79% to $1.9 million in 2022, then climbed by 6.83% to $2.0 million in 2023, then plummeted by 68.65% to $729,000 in 2024, then spiked by 130.86% to $1.7 million in 2025.
  • Its Receivables - Other was $1.7 million in Q3 2025, compared to $204,000 in Q2 2025 and $424,000 in Q1 2025.